Research ArticleOriginal Article
Open Access

Chitinase-3-like protein 1 levels in bipolar disorder

Basak Sahin, Ikbal Inanli, Ali M. Caliskan and Sema Uysal
Saudi Medical Journal January 2019, 40 (1) 26-32; DOI: https://doi.org/10.15537/smj.2019.1.23396

References

  1. ↵
    1. Price AL,
    2. Marzani-Nissen GR
    (2012) Bipolar disorders:a review. Am Fam Physician 85:483–493.
    OpenUrlPubMedWeb of Science
  2. ↵
    1. Leopold K,
    2. Reif A,
    3. Haack S,
    4. Bauer M,
    5. Bury D,
    6. Löffler A,
    7. et al.
    (2016) Type 2 diabetes and pre-diabetic abnormalities in patients with bipolar disorders. J Affect Disord 189:240–245.
    OpenUrl
  3. ↵
    1. Baum AE,
    2. Akula N,
    3. Cabanero M,
    4. Cardona I,
    5. Corona W,
    6. Klemens B,
    7. et al.
    (2008) A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 13:197–207.
    OpenUrlCrossRefPubMedWeb of Science
    1. Hashimoto K,
    2. Sawa A,
    3. Iyo M
    (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310–1316.
    OpenUrlCrossRefPubMedWeb of Science
    1. Houenou J,
    2. Frommberger J,
    3. Carde S,
    4. Glasbrenner M,
    5. Diener C,
    6. Leboyer M,
    7. et al.
    (2011) Neuroimaging-based markers of bipolar disorder:evidence from two meta-analyses. J Affect Disord 132:344–355.
    OpenUrlCrossRefPubMed
    1. Barnett JH,
    2. Huang J,
    3. Perlis RH,
    4. Young MM,
    5. Rosenbaum JF,
    6. Nierenberg AA,
    7. et al.
    (2011) Personality and bipolar disorder:dissecting state and trait associations between mood and personality. Psychol Med 41:1593–1604.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Chaudron LH,
    2. Pies RW
    (2003) The relationship between postpartum psychosis and bipolar disorder:a review. J Clin Psychiatry 64:1284–1292.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Merikangas KR,
    2. Jin R,
    3. He JP,
    4. Kessler RC,
    5. Lee S,
    6. Sampson NA,
    7. et al.
    (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68:241–251.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Hakala BE,
    2. White C,
    3. Recklies AD
    (1993) Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268:25803–25810.
    OpenUrlAbstract/FREE Full Text
    1. Shackelton LM,
    2. Mann DM,
    3. Millis AJ
    (1995) Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270:13076–13083.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Rehli M,
    2. Krause SW,
    3. Andreesen R
    (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43:221–225.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Rolstad S,
    2. Jakobsson J,
    3. Sellgren C,
    4. Ekman CJ,
    5. Blennow K,
    6. Zetterberg H,
    7. et al.
    (2015) Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration:a study of patients with bipolar disorder and healthy controls. PLoS One 10:e0127100.
    OpenUrlCrossRef
    1. Hellwig K,
    2. Kvartsberg H,
    3. Portelius E,
    4. Andreasson U,
    5. Oberstein TJ,
    6. Lewczuk P,
    7. et al.
    (2015) Neurogranin and YKL-40:independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res Ther 7:74.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Bonneh-Barkay D,
    2. Bissel SJ,
    3. Kofler J,
    4. Starkey A,
    5. Wang G,
    6. Wiley CA
    (2012) Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol 22:530–546.
    OpenUrlCrossRefPubMedWeb of Science
    1. Craig-Schapiro R,
    2. Perrin RJ,
    3. Roe CM,
    4. Xiong C,
    5. Carter D,
    6. Cairns NJ,
    7. et al.
    (2010) YKL-40:a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68:903–912.
    OpenUrlCrossRefPubMedWeb of Science
    1. Bonneh-Barkay D,
    2. Zagadailov P,
    3. Zou H,
    4. Niyonkuru C,
    5. Figley M,
    6. Starkey A,
    7. et al.
    (2010) YKL-40 expression in traumatic brain injury:an initial analysis. J Neurotrauma 27:1215–1223.
    OpenUrlCrossRefPubMedWeb of Science
    1. Zhang W,
    2. Kawanishi M,
    3. Miyake K,
    4. Kagawa M,
    5. Kawai N,
    6. Murao K,
    7. et al.
    (2010) Association between YKL-40 and adult primary astrocytoma. Cancer 116:2688–2697.
    OpenUrlPubMed
  18. ↵
    1. Bonneh-Barkay D,
    2. Wang G,
    3. Starkey A,
    4. Hamilton RL,
    5. Wiley CA
    (2010) In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 7:34.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Frye MA,
    2. Nassan M,
    3. Jenkins GD,
    4. Kung S,
    5. Veldic M,
    6. Palmer BA,
    7. et al.
    (2015) Feasibility of investigating differential proteomic expression in depression:implications for biomarker development in mood disorders. Transl Psychiatry 5:e689.
    OpenUrl
  20. ↵
    1. Von Elm E,
    2. Altman DG,
    3. Egger M,
    4. Pocock SJ,
    5. Gøtzsche PC,
    6. Vandenbroucke JP
    (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:Guidelines for reporting observational studies. PLoS Med 4:e296.
    OpenUrlCrossRefPubMed
  21. ↵
    (2013) American Psychiatric Association. Task Force on DSM 5. Diagnostic and Statistical Manual of Mental Disorders DSM-5 DSM-5:991.
    OpenUrl
  22. ↵
    1. Young RC,
    2. Biggs JT,
    3. Ziegler VE,
    4. Meyer DA
    (1978) A rating scale for mania:reliability, validity and sensitivity. Br J Psychiatry 133:429–435.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Akdemir A,
    2. Türkçapar MH,
    3. Orsel SD,
    4. Demirergi N,
    5. Dag I,
    6. Ozbay MH
    (2001) Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 42:161–165.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Hall RC
    (1995) Global assessment of functioning. A modified scale. Psychosomatics 36:267–275.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Karadağ F,
    2. Oral T,
    3. Yalçin FA,
    4. Erten E
    (2002) [Reliability and validity of Turkish translation of Young Mania Rating Scale]. Turk Psikiyatri Derg 13:107–114, [Turkish].
    OpenUrlPubMed
  26. ↵
    1. Busner J,
    2. Targum SD
    (2007) The clinical global impressions scale:applying a research tool in clinical practice. Psychiatry (Edgmont) 4:28–37.
    OpenUrl
  27. ↵
    1. Adejumo AO,
    2. Ikoba NA,
    3. Suleiman EA,
    4. Okagbue HI,
    5. Oguntunde PE,
    6. Odetunmibi OA,
    7. et al.
    (2017) Quantitative exploration of factors influencing psychotic disorder ailments in Nigeria. Data Brief 14:175–185.
    OpenUrl
  28. ↵
    1. Metsä-Simola N,
    2. Martikainen P,
    3. Monden CW
    (2018) Psychiatric morbidity and subsequent divorce:a couple-level register-based study in Finland. Soc Psychiatry Psychiatr Epidemiol 53:823–831.
    OpenUrlPubMed
  29. ↵
    1. Goodwin GM,
    2. Haddad PM,
    3. Ferrier IN,
    4. Aronson JK,
    5. Barnes T,
    6. Cipriani A,
    7. et al.
    (2016) Evidence-based guidelines for treating bipolar disorder:Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 30:495–553.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Conell J,
    2. Bauer R,
    3. Glenn T,
    4. Alda M,
    5. Ardau R,
    6. Baune BT,
    7. et al.
    (2016) Online information seeking by patients with bipolar disorder:results from an international multisite survey. Int J Bipolar Disord 4:17.
    OpenUrl
  31. ↵
    1. Jakobsson J,
    2. Bjerke M,
    3. Sahebi S,
    4. Isgren A,
    5. Ekman CJ,
    6. Sellgren C,
    7. et al.
    (2015) Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci 40:250–258.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Sklar P,
    2. Smoller JW,
    3. Fan J,
    4. Ferreira MA,
    5. Perlis RH,
    6. Chambert K,
    7. et al.
    (2008) Whole-genome association study of bipolar disorder. Mol Psychiatry 13:558–569.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    (2007) Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Wintemberg J,
    2. Yu M,
    3. Caman OK
    (2018) Health Warnings, Smoking Rules, and Smoking Status:A Cross-National Comparison of Turkey and the United States. Subst Use Misuse 53:963–971.
    OpenUrlCrossRef
  35. ↵
    1. Ertekin H,
    2. Sahin B,
    3. Caliskan AM,
    4. Inanli I,
    5. Ertekin YH
    (2018) Metabolic syndrome and vaspin in patients with bipolar disorder. Kaohsiung J Med Sci 34:522–528.
    OpenUrl
  36. ↵
    1. Hsu JH,
    2. Chien IC,
    3. Lin CH
    (2015) Increased risk of hyperlipidemia in patients with bipolar disorder:a population-based study. Gen Hosp Psychiatry 37:294–298.
    OpenUrlPubMed
  37. ↵
    1. Genc A,
    2. Kalelioglu T,
    3. Tasdemir A,
    4. Genc ES,
    5. Ozver I,
    6. Yesilbas D,
    7. et al.
    (2012) The prevalence of metabolic syndrome parameters among bipolar disorder outpatients on lithium monotherapy. Klin Psikofarmakol Bul 22:320–324.
    OpenUrl
  38. ↵
    1. Fernandes BS,
    2. Steiner J,
    3. Molendijk ML,
    4. Dodd S,
    5. Nardin P,
    6. Gonçalves CA,
    7. et al.
    (2016) C-reactive protein concentrations across the mood spectrum in bipolar disorder:a systematic review and meta-analysis. Lancet Psychiatry 3:1147–1156.
    OpenUrl
  39. ↵
    1. Isgren A,
    2. Sellgren C,
    3. Ekman CJ,
    4. Holmén-Larsson J,
    5. Blennow K,
    6. Zetterberg H,
    7. et al.
    (2017) Markers of neuroinflammation and neuronal injury in bipolar disorder:Relation to prospective clinical outcomes. Brain Behav Immun 65:195–201.
    OpenUrl
  40. ↵
    1. Rolstad S,
    2. Jakobsson J,
    3. Sellgren C,
    4. Isgren A,
    5. Ekman CJ,
    6. Bjerke M,
    7. et al.
    (2015) CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. Eur Neuropsychopharmacol 25:1091–1098.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section